Department of Pharmaceutical Botany, Faculty of Pharmacy, "George Emil Palade" University of Medicine, Pharmacy, Sciences and Technology of Târgu Mures, 540139 Târgu Mures, Romania.
Research Center of Medicinal and Aromatic Plants, "George Emil Palade" University of Medicine, Pharmacy, Sciences and Technology of Târgu Mures, 540139 Târgu Mures, Romania.
Nutrients. 2024 Oct 31;16(21):3730. doi: 10.3390/nu16213730.
BACKGROUND/OBJECTIVES: Type 2 diabetes mellitus (T2DM) is a disorder characterized by insulin resistance, hyperglycemia, and dyslipidemia. Myricetin, a flavonoid found in various plants, has shown potential anti-diabetic effects in murine studies. This meta-analysis aimed to evaluate the impact of myricetin supplementation on glucose metabolism and lipid profiles in mouse models of metabolic diseases.
A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines (PROSPERO: CRD42024591569). Studies involving mice with metabolic disease models and exclusively using myricetin supplementation were checked across four databases (Embase, Scopus, PubMed, and WoS) until 23rd September 2024. The primary outcomes assessed were blood glucose (BG), insulin levels, triacylglycerol (TAG), total cholesterol (TC), HDL, and LDL. A random-effects model was applied to estimate standardized mean differences (SMD), and SYRCLE's risk-of-bias tool for animal studies was used.
Twenty-one studies with 514 mice met the inclusion criteria. Myricetin supplementation significantly reduced BG (SMD = -1.45, CI: -1.91 to -0.99, < 0.00001, = 74%), insulin (SMD = -1.78, CI: -2.89 to -0.68, = 0.002, = 86%), TAG (SMD = -2.60, CI: -3.24 to -1.96, < 0.00001, = 81%), TC (SMD = -1.86, CI: -2.29 to -1.44, < 0.00001, = 62%), and LDL (SMD = -2.95, CI: -3.75 to -2.14, < 0.00001, = 74%). However, the effect on HDL was not statistically significant (SMD = 0.71, CI: -0.01 to 1.43, = 0.05, = 83%).
Myricetin supplementation improved glucose metabolism and lipid profiles in mouse models, suggesting its potential as a therapeutic agent for managing T2DM. However, further research is needed to confirm these findings in human studies.
背景/目的：2 型糖尿病（T2DM）是一种以胰岛素抵抗、高血糖和血脂异常为特征的疾病。杨梅素是一种存在于多种植物中的类黄酮，在小鼠研究中显示出有抗糖尿病的潜力。本荟萃分析旨在评估杨梅素补充剂对代谢疾病小鼠模型葡萄糖代谢和血脂谱的影响。
按照 PRISMA 指南（PROSPERO：CRD42024591569）进行系统评价和荟萃分析。在四个数据库（Embase、Scopus、PubMed 和 WoS）中检索了涉及代谢疾病模型的小鼠并单独使用杨梅素补充剂的研究，检索截至 2024 年 9 月 23 日。主要结局评估指标为血糖（BG）、胰岛素水平、三酰甘油（TAG）、总胆固醇（TC）、高密度脂蛋白（HDL）和低密度脂蛋白（LDL）。应用随机效应模型估计标准化均数差（SMD），并使用 SYRCLE 的动物研究偏倚风险工具。
21 项研究纳入了 514 只小鼠，符合纳入标准。杨梅素补充剂显著降低了 BG（SMD = -1.45，CI：-1.91 至-0.99， < 0.00001， = 74%）、胰岛素（SMD = -1.78，CI：-2.89 至-0.68， = 0.002， = 86%）、TAG（SMD = -2.60，CI：-3.24 至-1.96， < 0.00001， = 81%）、TC（SMD = -1.86，CI：-2.29 至-1.44， < 0.00001， = 62%）和 LDL（SMD = -2.95，CI：-3.75 至-2.14， < 0.00001， = 74%）。然而，HDL 的影响无统计学意义（SMD = 0.71，CI：-0.01 至 1.43， = 0.05， = 83%）。
杨梅素补充剂改善了小鼠模型的葡萄糖代谢和血脂谱，提示其作为 2 型糖尿病治疗药物的潜力。然而，还需要在人类研究中进一步证实这些发现。
